What this Trial Is About

Researchers are studying kidney diseases including IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis. The study collects serum and morning urine samples from patients diagnosed through kidney biopsy at the Nephrology Department of Qianfoshan Hospital in Shandong Province between January 2021 and December 2024. The goal is to use Raman spectroscopy to analyze chemical substances in these samples and develop a non-invasive diagnostic tool to assist in diagnosing kidney diseases and predicting treatment outcomes. The study involves scanning blood and urine samples with Raman spectroscopy to obtain spectral data. These spectra are analyzed using software to identify chemical bonds and compounds based on peak positions. Quantitative analysis equations are established from calibration curves, allowing accurate measurement of analyte concentrations in the samples. Multivariate statistical methods, such as principal component analysis and Mahalanobis distance models, are used to classify and predict different kidney disease types. Participants provide blood and urine samples, which are analyzed within two days of collection using Raman spectroscopy imaging. Researchers measure spectral peak intensities and areas and use this data for disease classification. The study monitors the presence and concentration of chemical substances in the samples to evaluate diagnostic potential. Participation includes sample collection, scanning, and data analysis over the study period from 2021 to 2024.

Raman Spectroscopy Diagnosis of Kidney Diseases